AstraZeneca Pharma India Limited has announced the resignation of Mr. Jesús Diaz-Ropero Esteso from his position as Non-Executive Director, effective immediately. The pharmaceutical company informed both BSE Limited and National Stock Exchange of India Limited about this board change on March 20, 2026, in compliance with regulatory disclosure requirements.

Board Transition Details

The resignation became effective on March 19, 2026, with Mr. Esteso citing a transition from current responsibilities as the reason for his departure. Along with stepping down from his directorship, he has also resigned from all Board Committees on which he served.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal intimation was signed by Company Secretary & Compliance Officer Tanya Sanish and submitted to both stock exchanges with the required documentation.

The filing included comprehensive annexures detailing the cessation particulars and a copy of the original resignation letter dated March 19, 2026. The resignation letter was brief, stating the director's decision to step down with immediate effect due to his transition from current responsibilities.

Documentation Process

AstraZeneca Pharma India Limited has provided all necessary documentation as per SEBI Master Circular requirements. The company requested both exchanges to take the intimation on record, ensuring full transparency regarding the board composition change.

The resignation represents a routine corporate governance matter, with the company maintaining proper disclosure protocols throughout the transition process.

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab Solution for Infusion, branded as Imfinzi, for an additional therapeutic indication. The approval, granted on March 16, 2026, specifically covers the treatment of unresectable hepatocellular carcinoma in patients without prior systemic treatment.

CDSCO Approval Details

The regulatory permission from the Directorate General of Health Services, Government of India, authorizes the import for sale and distribution of Durvalumab Solution for Infusion in two dosage strengths. This approval represents a significant milestone in expanding treatment options for liver cancer patients in India.

Market Authorization Impact

The CDSCO permission paves the way for marketing Durvalumab Solution (Imfinzi) in India for the specified additional indication, subject to receipt of related statutory approvals. This regulatory milestone strengthens AstraZeneca Pharma's oncology portfolio in the Indian market by providing oncologists with an advanced therapeutic option for managing hepatocellular carcinoma.

Clinical Significance

Durvalumab's approval for unresectable hepatocellular carcinoma addresses a critical medical need in India's healthcare system. The specific indication for treatment-naive patients represents those who have not previously received systemic therapy, expanding the treatment landscape for this challenging form of liver cancer.

The company formally communicated this development to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulation, 2015, highlighting the significance of this regulatory achievement for stakeholders.